Advanced in Pancreatoblastoma

Dr. Autumn J. Mcree

Hematology Oncology
170 Manning Dr, Chapel Hill, 
Chapel Hill, NC 
Clinical Trials:Currently Recruiting for 2 Trials
Advanced in Pancreatoblastoma
170 Manning Dr, Chapel Hill, 
Chapel Hill, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Autumn Mcree is a Hematologist Oncology provider in Chapel Hill, North Carolina. Dr. Mcree is rated as an Advanced provider by MediFind in the treatment of Pancreatoblastoma. Her top areas of expertise are Gastrointestinal Stromal Tumor, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Cholangiocarcinoma (Bile Duct Cancer).

Her clinical research consists of co-authoring 35 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in NC
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

170 Manning Dr, Chapel Hill, Chapel Hill, NC 27514

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer
Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drugs: Oxaliplatin, Leucovorin, Irinotecan hydrochloride, 5-FU
Study Phase: Phase 2
Ulixertinib (BVD-523) in Combination With Palbociclib in Patients With Advanced Solid Tumors With Expansion Cohort in Previously Treated Metastatic Pancreatic Cancer and Metastatic RAS-mutant and NF1-mutant (no BRAFV600 Mutations) Melanoma
Ulixertinib (BVD-523) in Combination With Palbociclib in Patients With Advanced Solid Tumors With Expansion Cohort in Previously Treated Metastatic Pancreatic Cancer and Metastatic RAS-mutant and NF1-mutant (no BRAFV600 Mutations) Melanoma
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Drug
Study Drugs: Ulixertinib, Palbociclib
Study Phase: Phase 1
Phase II Single-arm Study of the Combination of Palbociclib and Cetuximab in KRAS/NRAS/BRAF Wild-type Metastatic Colorectal Cancer
Phase II Single-arm Study of the Combination of Palbociclib and Cetuximab in KRAS/NRAS/BRAF Wild-type Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Cetuximab, Palbociclib
Study Phase: Phase 2
Phase II Multicenter Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma
Phase II Multicenter Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Drug
Study Drugs: Panitumumab, Nivolumab, Ipilimumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 3
Phase II Trial of ERK Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer
Phase II Trial of ERK Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drugs: Hydroxychloroquine Sulfate, LY3214996
Study Phase: Phase 2
A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas
A Single Arm, Multi-center Phase 2 Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas
Enrollment Status: Completed
Publish Date: December 19, 2023
Intervention Type: Drug
Study Drugs: Oxaliplatin, Leucovorin, 5 fluorouracil, Trastuzumab, Avelumab
Study Phase: Phase 2
Quantification and Characterization of Circulating Tumor Cells in Solid Tumors
Quantification and Characterization of Circulating Tumor Cells in Solid Tumors
Enrollment Status: Completed
Publish Date: September 28, 2022
Intervention Type: Other
An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002
An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002
Enrollment Status: Terminated
Publish Date: July 26, 2022
Intervention Type: Drug
Study Drugs: MLN0128, MLN0128 (RP2D), Sorafenib
Study Phase: Phase 1/Phase 2
A Multi-center Study of hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy
A Multi-center Study of hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy
Enrollment Status: Completed
Publish Date: November 19, 2018
Intervention Type: Biological
Study Phase: Phase 1
View 8 Less Clinical Trials

35 Total Publications

Phase II single-arm study of palbociclib and cetuximab in anti-EGFR naïve patients with KRAS/NRAS/BRAF wild-type, metastatic colorectal cancer.
Phase II single-arm study of palbociclib and cetuximab in anti-EGFR naïve patients with KRAS/NRAS/BRAF wild-type, metastatic colorectal cancer.
Journal: The oncologist
Published: July 15, 2025
Similar Doctors
Advanced in Pancreatoblastoma
Dr. Jose A. Ruiz
Hematology Oncology | Hematology | Oncology
Advanced in Pancreatoblastoma
Dr. Jose A. Ruiz
Hematology Oncology | Hematology | Oncology

Health Pavilion North Primary Care

6387 Ramsey Street, 
Fayetteville, NC 
 (52.5 miles away)
910-615-3840
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jose Ruiz is a Hematologist Oncology specialist and a Hematologist in Fayetteville, North Carolina. Dr. Ruiz has been practicing medicine for over 18 years and is rated as a Distinguished provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Angiosarcoma, and Familial Colorectal Cancer. Dr. Ruiz is currently accepting new patients.

Advanced in Pancreatoblastoma
Dr. Robert S. Wehbie
Hematology Oncology | Infectious Disease | Hematology
Advanced in Pancreatoblastoma
Dr. Robert S. Wehbie
Hematology Oncology | Infectious Disease | Hematology

Rex Hospital Inc

300 Health Park Dr, 
Garner, NC 
 (30.4 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Wehbie is a Hematologist Oncology specialist and an Infectious Disease provider in Garner, North Carolina. Dr. Wehbie is rated as a Distinguished provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Familial Pancreatic Cancer, Acute Mountain Sickness, Paget Disease of the Breast, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Wehbie is currently accepting new patients.

Advanced in Pancreatoblastoma
Dr. Tariq Nazir
Hematology Oncology | Hematology | Oncology
Advanced in Pancreatoblastoma
Dr. Tariq Nazir
Hematology Oncology | Hematology | Oncology

Cumberland County Hospital System Inc

6387 Ramsey St, Unit 100, 
Fayetteville, NC 
 (52.5 miles away)
910-615-3879
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Tariq Nazir is a Hematologist Oncology specialist and a Hematologist in Fayetteville, North Carolina. Dr. Nazir is rated as a Distinguished provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Familial Colorectal Cancer, and Colorectal Cancer. Dr. Nazir is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcree's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 8 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile